News
STAA
19.08
-3.64%
-0.72
STAAR Surgical authorizes $50M share buyback
Seeking Alpha · 1h ago
Staar Surgical approves $50M share repurchase authorization
TipRanks · 1h ago
*STAAR Surgical Board Approves $50 Million Share Repurchase Authorization >STAA
Dow Jones · 1h ago
Staar Surgical Is Maintained at Buy by Jefferies
Dow Jones · 2d ago
Staar Surgical Price Target Cut to $23.00/Share From $28.00 by Jefferies
Dow Jones · 2d ago
Staar Surgical price target lowered to $23 from $28 at Jefferies
TipRanks · 2d ago
Weekly Report: what happened at STAA last week (0914-0918)?
Weekly Report · 3d ago
Weekly Report: what happened at STAA last week (0907-0911)?
Weekly Report · 09/14 10:26
Staar Surgical Reappoints David Bailey to Drive Growth
TipRanks · 09/10 10:37
STAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision Correction
Barchart · 09/10 06:00
Staar Surgical names David Bailey as Chief Commercial Officer
TipRanks · 09/09 19:35
*STAAR Surgical Names Former CEO David Bailey As Chief Commercial Officer >STAA
Dow Jones · 09/09 19:33
Staar Surgical Brings Back Former CEO Bailey as Commercial Chief
Dow Jones · 09/08 20:19
Weekly Report: what happened at STAA last week (0831-0904)?
Weekly Report · 09/07 10:19
Staar Surgical names Ben Park CTO
TipRanks · 09/02 20:06
*STAAR Surgical: Names Medtech Innovator and Platform Builder Ben Park as Chief Technology Officer
Dow Jones · 09/02 20:01
Weekly Report: what happened at STAA last week (0824-0828)?
Weekly Report · 08/31 10:27
Staar Surgical Advances Next‑Gen ICL Study, Signaling Long‑Term Growth Potential
TipRanks · 08/27 16:31
Staar Surgical Targets Presbyopia Growth With New Trifocal ICL Trial
TipRanks · 08/27 16:30
Weekly Report: what happened at STAA last week (0817-0821)?
Weekly Report · 08/24 10:28
More
Webull provides a variety of real-time STAA stock news. You can receive the latest news about Staar Surg through multiple platforms. This information may help you make smarter investment decisions.
About STAA
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also markets and sells an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company's principal products are ICLs used in refractive surgery, including its EVO family of lenses.